Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
5
3
1
0
RUBIUS THERAPEUTICSCS INC Share · US78116T1034 · RUBY · A2JQ3H (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of RUBIUS THERAPEUTICSCS INC
Analyst Grade Summary
No Price
Invested Funds
The following funds have invested in RUBIUS THERAPEUTICSCS INC:
Fund | Vol. in million 67,57 | Percentage (%) 0,16 % |
Company Profile for RUBIUS THERAPEUTICSCS INC Share
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Company Data
Name RUBIUS THERAPEUTICSCS INC
Company Rubius Therapeutics, Inc.
Symbol RUBY
Website
https://www.rubiustx.com
Primary Exchange 
NASDAQ
NASDAQ
WKN A2JQ3H
ISIN US78116T1034
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Laurence A. Turka
Country United States of America
Currency USD
Employees 0,0 T
Address 399 Binney Street, 02139 Cambridge
IPO Date 2018-07-18
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | RUBY |
More Shares
Investors who hold RUBIUS THERAPEUTICSCS INC also have the following shares in their portfolio:
